Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.

Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M, Maloney JA, Meilandt WJ, Bumbaca D, Gadkar K, Hoyte K, Luk W, Lu Y, Ernst JA, Scearce-Levie K, Couch JA, Dennis MS, Watts RJ.

Sci Transl Med. 2014 Nov 5;6(261):261ra154. doi: 10.1126/scitranslmed.3009835.

PMID:
25378646
2.

Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier.

Couch JA, Yu YJ, Zhang Y, Tarrant JM, Fuji RN, Meilandt WJ, Solanoy H, Tong RK, Hoyte K, Luk W, Lu Y, Gadkar K, Prabhu S, Ordonia BA, Nguyen Q, Lin Y, Lin Z, Balazs M, Scearce-Levie K, Ernst JA, Dennis MS, Watts RJ.

Sci Transl Med. 2013 May 1;5(183):183ra57, 1-12. doi: 10.1126/scitranslmed.3005338.

3.

A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.

Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jönsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K.

Nature. 2012 Aug 2;488(7409):96-9. doi: 10.1038/nature11283.

PMID:
22801501
4.

Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice.

Deng R, Meng YG, Hoyte K, Lutman J, Lu Y, Iyer S, DeForge LE, Theil FP, Fielder PJ, Prabhu S.

MAbs. 2012 Jan-Feb;4(1):101-9. doi: 10.4161/mabs.4.1.18543.

5.

Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.

Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ, Dennis MS.

Sci Transl Med. 2011 May 25;3(84):84ra44. doi: 10.1126/scitranslmed.3002230.

6.

A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo.

Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, Heise CE, Hoyte K, Luk W, Lu Y, Peng K, Wu P, Rouge L, Zhang Y, Lazarus RA, Scearce-Levie K, Wang W, Wu Y, Tessier-Lavigne M, Watts RJ.

Sci Transl Med. 2011 May 25;3(84):84ra43. doi: 10.1126/scitranslmed.3002254.

7.

Components of speech prosody and their use in detection of syntactic structure by older adults.

Hoyte KJ, Brownell H, Wingfield A.

Exp Aging Res. 2009 Jan-Mar;35(1):129-51. doi: 10.1080/03610730802565091.

8.

Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.

Chaturvedi S, Zivin J, Breazna A, Amarenco P, Callahan A, Goldstein LB, Hennerici M, Sillesen H, Rudolph A, Welch MA; SPARCL Investigators.

Neurology. 2009 Feb 24;72(8):688-94. doi: 10.1212/01.wnl.0000327339.55844.1a. Epub 2008 Sep 3.

PMID:
18768917
9.

Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.

Goldstein LB, Amarenco P, Lamonte M, Gilbert S, Messig M, Callahan A, Hennerici M, Sillesen H, Welch KM; SPARCL Investigators.

Stroke. 2008 Sep;39(9):2444-8. doi: 10.1161/STROKEAHA.107.513747. Epub 2008 Jul 10.

10.
11.

Cellular laserfection.

Rhodes K, Clark I, Zatcoff M, Eustaquio T, Hoyte KL, Koller MR.

Methods Cell Biol. 2007;82:309-33.

PMID:
17586262
12.

Variable solutions to the same problem: aberrant practice effects in object naming by three aphasic patients.

Wingfield A, Brownell H, Hoyte KJ.

Brain Lang. 2006 Jun;97(3):351-6. Epub 2005 Dec 28.

PMID:
16386289
13.

Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study.

Sherman DG, Kim SG, Boop BS, Corley SD, Dimarco JP, Hart RG, Haywood LJ, Hoyte K, Kaufman ES, Kim MH, Nasco E, Waldo AL; National Heart, Lung, and Blood Institute AFFIRM Investigators.

Arch Intern Med. 2005 May 23;165(10):1185-91.

PMID:
15911734
14.

Transgenic overexpression of dystroglycan does not inhibit muscular dystrophy in mdx mice.

Hoyte K, Jayasinha V, Xia B, Martin PT.

Am J Pathol. 2004 Feb;164(2):711-8.

15.

Inhibition of dystroglycan cleavage causes muscular dystrophy in transgenic mice.

Jayasinha V, Nguyen HH, Xia B, Kammesheidt A, Hoyte K, Martin PT.

Neuromuscul Disord. 2003 Jun;13(5):365-75.

PMID:
12798792
16.

Overexpression of the CT GalNAc transferase inhibits muscular dystrophy in a cleavage-resistant dystroglycan mutant mouse.

Jayasinha V, Hoyte K, Xia B, Martin PT.

Biochem Biophys Res Commun. 2003 Mar 21;302(4):831-6.

PMID:
12646245
19.

Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice.

Nguyen HH, Jayasinha V, Xia B, Hoyte K, Martin PT.

Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5616-21.

20.

Overexpression of the CT GalNAc transferase in skeletal muscle alters myofiber growth, neuromuscular structure, and laminin expression.

Xia B, Hoyte K, Kammesheidt A, Deerinck T, Ellisman M, Martin PT.

Dev Biol. 2002 Feb 1;242(1):58-73.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk